NCT02424396View on ClinicalTrials.gov

Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 13, 2016

Primary Completion Date

October 11, 2019

Study Completion Date

June 15, 2020

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

IL2

Induction period: repeated administration of low-dose IL-2 Maintenance period: treatment with IL-2

DRUG

Placebo

Trial Locations (3)

75013

Centre d'investigation Clinique - Pitié salpêtrière, Paris

Centre d'investigation clinique Biothérapie Immunologie (CIC-BTi) - Groupe Hospitalier Pitié-Salpêtrière - AP-HP, Paris

Département des maladies du système nerveux et Centre d'investigation clinique - Groupe Hospitalier Pitié-Salpêtrière - AP-HP, Paris

All Listed Sponsors
collaborator

Fondation ARSEP/AFM

UNKNOWN

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02424396 - Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis | Biotech Hunter | Biotech Hunter